Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?

Treatment of relapsed/refractory diffuse large B‐cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR‐T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET‐derived parameters, the report of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisselbrecht, Christian, Sibon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086831/
https://www.ncbi.nlm.nih.gov/pubmed/36120952
http://dx.doi.org/10.1111/bjh.18468
_version_ 1785022228584202240
author Gisselbrecht, Christian
Sibon, David
author_facet Gisselbrecht, Christian
Sibon, David
author_sort Gisselbrecht, Christian
collection PubMed
description Treatment of relapsed/refractory diffuse large B‐cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR‐T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET‐derived parameters, the report of Cherng and colleagues suggests that patients with positive residual mass can have a five‐year survival of 54% with standard treatment.
format Online
Article
Text
id pubmed-10086831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100868312023-04-12 Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant? Gisselbrecht, Christian Sibon, David Br J Haematol Commentaries Treatment of relapsed/refractory diffuse large B‐cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR‐T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET‐derived parameters, the report of Cherng and colleagues suggests that patients with positive residual mass can have a five‐year survival of 54% with standard treatment. John Wiley and Sons Inc. 2022-09-19 2023-01 /pmc/articles/PMC10086831/ /pubmed/36120952 http://dx.doi.org/10.1111/bjh.18468 Text en © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentaries
Gisselbrecht, Christian
Sibon, David
Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title_full Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title_fullStr Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title_full_unstemmed Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title_short Do we have to exclude all relapsed diffuse large B‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
title_sort do we have to exclude all relapsed diffuse large b‐cell lymphoma patients not in complete remission from autologous stem cell transplant?
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086831/
https://www.ncbi.nlm.nih.gov/pubmed/36120952
http://dx.doi.org/10.1111/bjh.18468
work_keys_str_mv AT gisselbrechtchristian dowehavetoexcludeallrelapseddiffuselargebcelllymphomapatientsnotincompleteremissionfromautologousstemcelltransplant
AT sibondavid dowehavetoexcludeallrelapseddiffuselargebcelllymphomapatientsnotincompleteremissionfromautologousstemcelltransplant

Ejemplares similares